Hepatocellular Carcinoma | Tim Greten, MD

published 1 month ago by Dr Neil Love

Hepatocellular Carcinoma Update, Issue 1, 2020 — Part 2: Our interview with Dr Greten highlights the following topics as well as cases from his practice: Adjuvant treatment of HCC: Prospect for immunotherapy (00:00) Immune landscape of the liver and role of the microbiome (04:18) Ongoing trials evaluating immunotherapy in the (neo)adjuvant setting for patients with HCC (07:04) Role of immunotherapy and targeted therapy in the management of cholangiocarcinoma (09:49) Mechanism for the synergy between immune checkpoint inhibitors and anti-angiogenic therapies (11:16) Perspective on an antibody- versus a tyrosine kinase inhibitor-based approach to targeting VEGF (14:00) Development of shellfish allergy after exposure to dual immune checkpoint blockade with durvalumab and tremelimumab (17:03) Spectrum of immune-related adverse events associated with checkpoint inhibitors (18:47) Background and design of the Phase III IMbrave150 trial (20:03) Exclusion of patients with bleeding or high risk of bleeding with untreated varices from the IMbrave150 trial (21:34) IMbrave150: Activity and tolerability of atezolizumab/bevacizumab versus sorafenib (24:32) Historical response rates with single-agent tyrosine kinase inhibitors or anti-PD-1/PD-L1 antibodies (27:46) Potential clinical role of atezolizumab/bevacizumab as first-line therapy for patients with advanced HCC (28:56) Selection and sequencing of therapies for patients with HCC (31:27) Ongoing investigation of immune checkpoint inhibitor combinations (34:05) Activity of immune checkpoint inhibitors in patients with HCC (35:57) Case: A man in his mid-60s with a history of hepatitis C receives cabozantinib for metastatic HCC after experiencing disease progression on lenvatinib and pembrolizumab (38:19) Side effects associated with sorafenib and lenvatinib (41:11) Efficacy and tolerability of pembrolizumab for HCC (43:51) Approach to first- and second-line treatment for HCC (47:56) Case: A man in his early 40s with chronic hepatitis B and metastatic HCC has no evidence of disease after treatment with pembrolizumab and surgical resection (50:55) Case: A man in his mid-40s with uncontrolled hepatitis C develops transaminitis after treatment with sorafenib for HCC (55:14) CME information and select publications

more episodes from Research To Practice | Oncology Videos